Free Trial

Guardant Health (GH) Stock Forecast & Price Target

Guardant Health logo
$41.36 -0.30 (-0.72%)
As of 04:00 PM Eastern

Guardant Health - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
22

Based on 22 Wall Street analysts who have issued ratings for Guardant Health in the last 12 months, the stock has a consensus rating of "Buy." Out of the 22 analysts, 21 have given a buy rating, and 1 has given a strong buy rating for GH.

Consensus Price Target

$52.32
26.49% Upside
According to the 22 analysts' twelve-month price targets for Guardant Health, the average price target is $52.32. The highest price target for GH is $70.00, while the lowest price target for GH is $32.00. The average price target represents a forecasted upside of 26.49% from the current price of $41.36.
Get the Latest News and Ratings for GH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Guardant Health and its competitors.

Sign Up

GH Analyst Ratings Over Time

TypeCurrent Forecast
5/13/24 to 5/13/25
1 Month Ago
4/13/24 to 4/13/25
3 Months Ago
2/13/24 to 2/12/25
1 Year Ago
5/14/23 to 5/13/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
21 Buy rating(s)
20 Buy rating(s)
16 Buy rating(s)
10 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$52.32$49.00$42.63$35.78
Forecasted Upside26.49% Upside12.10% Upside-6.07% Downside49.07% Upside
Consensus Rating
Buy
Buy
Buy
Moderate Buy

GH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Guardant Health Stock vs. The Competition

TypeGuardant HealthMedical CompaniesS&P 500
Consensus Rating Score
3.05
2.81
2.54
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside26.49% Upside4,488.53% Upside13.59% Upside
News Sentiment Rating
Positive News

See Recent GH News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/6/2025Piper Sandler
2 of 5 stars
David Westenberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.00+37.36%
5/5/2025Scotiabank
5 of 5 stars
 Reiterated RatingOutperform ➝ Outperform
5/1/2025Canaccord Genuity Group
2 of 5 stars
Kyle Mikson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$60.00 ➝ $65.00+32.95%
5/1/2025TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Dan Brennan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$56.00 ➝ $60.00+24.86%
5/1/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$55.00 ➝ $60.00+24.86%
5/1/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Daniel Arias
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$53.00 ➝ $60.00+24.86%
5/1/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Dan Leonard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$65.00 ➝ $70.00+44.33%
4/10/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Anthony Petrone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00+25.37%
3/26/2025Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mason Carrico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$55.00 ➝ $55.00+18.57%
3/6/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Shannon O'Callaghan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$42.00 ➝ $52.00+26.78%
2/24/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Subbu Nambi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$56.00 ➝ $56.00+29.86%
2/21/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matthew Sykes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$49.00 ➝ $56.00+31.12%
2/21/2025Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Cooper
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$39.00 ➝ $59.00+32.80%
2/21/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Rachel Vatnsdal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$50.00 ➝ $55.00+18.48%
10/30/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$40.00 ➝ $35.00+49.51%
10/17/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$60.00 ➝ $50.00+131.27%
8/8/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$40.00 ➝ $45.00+48.27%
8/8/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$41.00 ➝ $42.00+38.61%
8/8/2024Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$28.00 ➝ $37.00+21.79%
7/30/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$45.00 ➝ $50.00+37.51%
7/18/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$28.00 ➝ $40.00+22.89%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$32.00+17.09%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoveragePeer Perform
9/8/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:26 PM ET.


GH Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Guardant Health is $52.32, with a high forecast of $70.00 and a low forecast of $32.00.

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 21 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GH shares.

According to analysts, Guardant Health's stock has a predicted upside of 26.49% based on their 12-month stock forecasts.

Over the previous 90 days, Guardant Health's stock had 1 upgrade by analysts.

Analysts like Guardant Health more than other "medical" companies. The consensus rating for Guardant Health is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GH compares to other companies.


This page (NASDAQ:GH) was last updated on 5/13/2025 by MarketBeat.com Staff
From Our Partners